| human | Q5 |
| P950 | National Library of Spain ID | XX5606789 |
| P496 | ORCID iD | 0000-0002-4652-4825 |
| P1153 | Scopus author ID | 6701726712 |
| P214 | VIAF cluster ID | 2146822188107381493 |
| P10832 | WorldCat Entities ID | E39PBJgmHXPWDD74TfhgpCj3cP |
| P735 | given name | Antonio | Q7141520 |
| Antonio | Q7141520 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q57759536 | A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome |
| Q58010175 | A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis |
| Q51697220 | A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma |
| Q46905102 | A new modified prophylactic scheme against liposomal cytarabine-induced arachnoiditis in adult patients with lymphoma. |
| Q86859965 | A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma |
| Q94706496 | A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia |
| Q58010127 | Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma |
| Q58010162 | Acute myeloid dendritic cell leukaemia with specific cutaneous involvement: a diagnostic challenge |
| Q83454474 | Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study |
| Q93018518 | Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification |
| Q38862949 | Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells. |
| Q40320592 | Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. |
| Q38405004 | Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia |
| Q73786509 | Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens |
| Q51784419 | Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53. |
| Q88149119 | Blastic Plasmacytoid Dendritic Cell Neoplasm Associated with Dystrophic Xanthomatosis after Chemotherapy |
| Q48821642 | Central nervous system involvement from primary cutaneous large B-cell lymphoma of the leg. |
| Q36859222 | Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial |
| Q99567439 | Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms |
| Q91671688 | Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas |
| Q82871794 | Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain |
| Q34093532 | Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. |
| Q84365547 | Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era |
| Q43293479 | Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type |
| Q46607442 | Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study |
| Q87241674 | Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome |
| Q39841853 | Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. |
| Q83325633 | Cutaneous lymphomas showing prominent granulomatous component: clinicopathological features in a series of 16 cases |
| Q54427707 | Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. |
| Q33828585 | Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. |
| Q81213958 | Diarrheic syndrome as a clinical sign of intestinal infiltration in progressive B-cell chronic lymphocytic leukemia |
| Q35536636 | Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14. |
| Q42275445 | Diffuse large B-cell lymphoma associated with chronic inflammation in metallic implant. |
| Q35809271 | Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry |
| Q46726915 | Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 1. Synchronous mucosa-associated lymphoid tissue lymphoma and gastrointestinal stromal tumors of the stomach |
| Q77169287 | Engraftment syndrome and survival after respiratory failure post-bone marrow transplantation |
| Q91714421 | Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era |
| Q36068948 | Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice |
| Q41643942 | First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial |
| Q33408270 | First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial [...] |
| Q44668352 | Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). |
| Q79137726 | Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study |
| Q36399362 | Granulomatous dermatitis with enlarged histiocytes: a characteristic pattern of granulocyte colony-stimulating factor. Report of two cases and review of the literature. |
| Q37618814 | Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). |
| Q27312570 | Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics |
| Q80142957 | Hypopituitarism associated with mycotic aneurysm of the cavernous carotid artery in a renal transplant recipient |
| Q51851505 | Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. |
| Q53099332 | Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. |
| Q82654452 | Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice |
| Q44114704 | Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. |
| Q40245653 | Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. |
| Q77829113 | Indolent course as presentation in t-prolymphocytic leukaemia |
| Q42409619 | Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease |
| Q45951618 | Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. |
| Q84737734 | Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma |
| Q83489942 | Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma |
| Q46693519 | Langerhans' cell histiocytosis mimicking relapse in a patient with follicular lymphoma |
| Q40022297 | Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. |
| Q85917538 | Lenalidomide-induced paronychia |
| Q91821663 | Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population |
| Q40671200 | Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. |
| Q48250913 | Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. |
| Q40374056 | Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial |
| Q88027873 | MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma |
| Q87466868 | Metronomic chemotherapy for advanced and refractory cutaneous T-cell lymphoma treatment |
| Q37607918 | MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis |
| Q58010136 | Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients |
| Q112700231 | Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA |
| Q53551450 | Monoclonal cryoglobulinemia: the first manifestation of gastric marginal B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). |
| Q83442793 | NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma |
| Q57279370 | New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY) |
| Q58041476 | Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification |
| Q81921906 | Persistent monoclonality after histological remission in gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy and/or surgery: influence of t(11;18)(q21;q21) |
| Q81322465 | Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab |
| Q73628821 | Pneumonia caused by Micrococcus species in a neutropenic patient with acute leukemia |
| Q45928632 | Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. |
| Q44577565 | Posttransplant lymphoproliferative disease: treatment and outcome in renal transplant recipients |
| Q47948560 | Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment. |
| Q50528416 | Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features |
| Q73073336 | Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia |
| Q81503138 | Progressive painless swelling of glans penis: uncommon clinical manifestation of systemic non-Hodgkin's lymphoma |
| Q79909161 | Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease |
| Q46302136 | R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. |
| Q79952961 | Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution |
| Q38548134 | Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. |
| Q90411174 | Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 |
| Q47984316 | Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group |
| Q47219319 | Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases |
| Q43743732 | Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. |
| Q37038412 | Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. |
| Q53139425 | Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series |
| Q34532146 | Study of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcome |
| Q42952014 | Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin |
| Q34636362 | The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. |
| Q53497330 | Thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma concurrently diagnosed with a diffuse large B-cell lymphoma localized in the neck |
| Q87409487 | Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma |
| Q40371971 | Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2 -microglobulin yields a more accurate GELTAMO-IPI. |
| Q54502320 | Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. |
| Q87540229 | [Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years] |
Search more.